SAN DIEGO & RIYADH — February 20, 2026 — Immunotherapy innovator ImmunityBio has announced a strategic partnership with regional biopharma stakeholders and Cigalah Healthcare to launch ANKTIVA® (nogapendekin alfa inbakicept) in Saudi Arabia, expanding access to advanced immuno-oncology therapies for patients with bladder and lung cancers. The collaboration marks a significant milestone in global oncology commercialization, bringing next-generation immune-activating biologics into one of the Middle East’s fastest-growing specialty care markets while reinforcing international momentum for cytokine-based cancer immunotherapies.
Science Significance
The partnership underscores the growing scientific relevance of cytokine-based immunotherapy platforms designed to activate natural killer (NK) cells and CD8+ T cells to enhance anti-tumor immune responses. ANKTIVA, an IL-15 superagonist, represents a novel class of biologics engineered to stimulate durable immune surveillance without the toxicity profile historically associated with high-dose cytokine therapies. Clinical evidence supporting its use in bladder cancer — particularly in BCG-unresponsive non-muscle invasive disease — demonstrates meaningful tumor response rates, immune memory activation, and improved disease control. Its expansion into lung cancer settings further reflects the translational potential of innate immune system modulation as a complementary strategy alongside checkpoint inhibitors and chemotherapy.
Regulatory Significance
From a regulatory perspective, the launch signals cross-border therapeutic authorization alignment and market access advancement within the Saudi Food and Drug Authority (SFDA) framework. Introducing a complex biologic immunotherapy into the Kingdom requires rigorous review of clinical efficacy, biologics manufacturing quality, pharmacovigilance infrastructure, and cold-chain distribution compliance. The collaboration demonstrates ImmunityBio’s ability to navigate multi-regional regulatory pathways while supporting localization of advanced oncology standards. It also reflects the broader trend of Middle Eastern regulators accelerating access to breakthrough biologics through reliance models, international data recognition, and oncology fast-track mechanisms.
Business Significance
Advertisement
Commercially, the agreement strengthens ImmunityBio’s global expansion strategy by leveraging Cigalah Healthcare’s regional distribution scale and institutional relationships. Saudi Arabia represents a high-value oncology growth market driven by rising cancer incidence, government healthcare investment, and Vision 2030 life-sciences diversification goals. The launch enables market penetration for ANKTIVA across hospital networks, oncology centers, and specialty infusion providers, positioning the therapy competitively within the immuno-oncology landscape. Strategic regional partnerships reduce commercialization risk while accelerating revenue channels, real-world evidence generation, and physician adoption across Gulf Cooperation Council (GCC) markets.
Patients’ Significance
For patients, the partnership expands access to innovative immune-activating therapies targeting difficult-to-treat cancers. Individuals with bladder cancer who fail standard intravesical BCG therapy often face limited bladder-sparing options, while lung cancer patients require new modalities capable of improving survival durability. ANKTIVA’s mechanism offers the potential for enhanced immune response without systemic chemotherapy burden, supporting quality-of-life preservation and long-term disease management. Regional availability also reduces treatment travel barriers, enabling patients to receive cutting-edge biologic therapy within national oncology care systems.
Policy Significance
Health policy implications extend to national cancer control planning, biologics localization, and immunotherapy reimbursement frameworks. Saudi Arabia continues to invest in precision medicine, immuno-oncology infrastructure, and domestic biopharma capability building. The introduction of ANKTIVA aligns with policy priorities to expand access to breakthrough cancer therapies, strengthen biologics procurement pathways, and integrate advanced immunotherapies into public oncology programs. Partnerships of this nature may also catalyze future clinical trials, technology transfer initiatives, and regional manufacturing collaborations.
The launch of ANKTIVA in Saudi Arabia marks a convergence of scientific innovation, regulatory advancement, and global oncology access expansion. By combining ImmunityBio’s next-generation cytokine immunotherapy platform with Cigalah Healthcare’s regional commercialization strength, the partnership accelerates delivery of transformative cancer treatments into emerging specialty markets. As immuno-oncology continues evolving beyond checkpoint inhibition toward immune system activation and cellular orchestration, initiatives like this reinforce the global shift toward biologic precision therapies designed to improve survival while redefining standards of cancer care.
Source: ImmunityBio press release
